Online inquiry

IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14772MR)

This product GTTS-WQ14772MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14772MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4710MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ14236MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ7427MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ13518MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ5598MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ6049MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ4075MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ7231MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW